Tags

Type your tag names separated by a space and hit enter

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):249-254.MM

Abstract

During September 22, 2021-February 6, 2022, approximately 82.6 million U.S. residents aged ≥18 years received a COVID-19 vaccine booster dose.* The Food and Drug Administration (FDA) has authorized a booster dose of either the same product administered for the primary series (homologous) or a booster dose that differs from the product administered for the primary series (heterologous). These booster authorizations apply to all three COVID-19 vaccines used in the United States (1-3).† The Advisory Committee on Immunization Practices (ACIP) recommended preferential use of an mRNA COVID-19 vaccine (mRNA-1273 [Moderna] or BNT162b2 [Pfizer-BioNTech]) for a booster, even for persons who received the Ad26.COV2.S (Janssen [Johnson & Johnson]) COVID-19 vaccine for their single-dose primary series.§ To characterize the safety of COVID-19 vaccine boosters among persons aged ≥18 years during September 22, 2021-February 6, 2022, CDC reviewed adverse events and health impact assessments following receipt of a booster that were reported to v-safe, a voluntary smartphone-based safety surveillance system for adverse events after COVID-19 vaccination, and adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety surveillance system managed by CDC and FDA. Among 721,562 v-safe registrants aged ≥18 years who reported receiving a booster, 88.8% received homologous COVID-19 mRNA vaccination. Among registrants who reported a homologous COVID-19 mRNA booster dose, systemic reactions were less frequent following the booster (58.4% [Pfizer-BioNTech] and 64.4% [Moderna], respectively) than were those following dose 2 (66.7% and 78.4%, respectively). The adjusted odds of reporting a systemic reaction were higher following a Moderna COVID-19 vaccine booster, irrespective of the vaccine received for the primary series. VAERS has received 39,286 reports of adverse events after a COVID-19 mRNA booster vaccination for adults aged ≥18 years, including 36,282 (92.4%) nonserious and 3,004 (7.6%) serious events. Vaccination providers should educate patients that local and systemic reactions are expected following a homologous COVID-19 mRNA vaccine booster; however, these reactions appear less common than those following dose 2 of an mRNA-based vaccine. CDC and FDA will continue to monitor vaccine safety and provide data to guide vaccine recommendations and protect public health.

Links

PMC Free PDF

Authors

Hause AM
No affiliation info available
Baggs J
No affiliation info available
Marquez P
No affiliation info available
Myers TR
No affiliation info available
Su JR
No affiliation info available
Blanc PG
No affiliation info available
Gwira Baumblatt JA
No affiliation info available
Woo EJ
No affiliation info available
Gee J
No affiliation info available
Shimabukuro TT
No affiliation info available
Shay DK
No affiliation info available

MeSH

AdultAdverse Drug Reaction Reporting SystemsAgedCOVID-19COVID-19 VaccinesFemaleHumansImmunization, SecondaryMaleMiddle AgedSARS-CoV-2SafetyUnited States

Pub Type(s)

Journal Article

Language

eng

PubMed ID

35176008

Citation

Hause, Anne M., et al. "Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022." MMWR. Morbidity and Mortality Weekly Report, vol. 71, no. 7, 2022, pp. 249-254.
Hause AM, Baggs J, Marquez P, et al. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):249-254.
Hause, A. M., Baggs, J., Marquez, P., Myers, T. R., Su, J. R., Blanc, P. G., Gwira Baumblatt, J. A., Woo, E. J., Gee, J., Shimabukuro, T. T., & Shay, D. K. (2022). Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022. MMWR. Morbidity and Mortality Weekly Report, 71(7), 249-254. https://doi.org/10.15585/mmwr.mm7107e1
Hause AM, et al. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):249-254. PubMed PMID: 35176008.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022. AU - Hause,Anne M, AU - Baggs,James, AU - Marquez,Paige, AU - Myers,Tanya R, AU - Su,John R, AU - Blanc,Phillip G, AU - Gwira Baumblatt,Jane A, AU - Woo,Emily Jane, AU - Gee,Julianne, AU - Shimabukuro,Tom T, AU - Shay,David K, Y1 - 2022/02/18/ PY - 2022/2/17/entrez PY - 2022/2/18/pubmed PY - 2022/2/26/medline SP - 249 EP - 254 JF - MMWR. Morbidity and mortality weekly report JO - MMWR Morb Mortal Wkly Rep VL - 71 IS - 7 N2 - During September 22, 2021-February 6, 2022, approximately 82.6 million U.S. residents aged ≥18 years received a COVID-19 vaccine booster dose.* The Food and Drug Administration (FDA) has authorized a booster dose of either the same product administered for the primary series (homologous) or a booster dose that differs from the product administered for the primary series (heterologous). These booster authorizations apply to all three COVID-19 vaccines used in the United States (1-3).† The Advisory Committee on Immunization Practices (ACIP) recommended preferential use of an mRNA COVID-19 vaccine (mRNA-1273 [Moderna] or BNT162b2 [Pfizer-BioNTech]) for a booster, even for persons who received the Ad26.COV2.S (Janssen [Johnson & Johnson]) COVID-19 vaccine for their single-dose primary series.§ To characterize the safety of COVID-19 vaccine boosters among persons aged ≥18 years during September 22, 2021-February 6, 2022, CDC reviewed adverse events and health impact assessments following receipt of a booster that were reported to v-safe, a voluntary smartphone-based safety surveillance system for adverse events after COVID-19 vaccination, and adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety surveillance system managed by CDC and FDA. Among 721,562 v-safe registrants aged ≥18 years who reported receiving a booster, 88.8% received homologous COVID-19 mRNA vaccination. Among registrants who reported a homologous COVID-19 mRNA booster dose, systemic reactions were less frequent following the booster (58.4% [Pfizer-BioNTech] and 64.4% [Moderna], respectively) than were those following dose 2 (66.7% and 78.4%, respectively). The adjusted odds of reporting a systemic reaction were higher following a Moderna COVID-19 vaccine booster, irrespective of the vaccine received for the primary series. VAERS has received 39,286 reports of adverse events after a COVID-19 mRNA booster vaccination for adults aged ≥18 years, including 36,282 (92.4%) nonserious and 3,004 (7.6%) serious events. Vaccination providers should educate patients that local and systemic reactions are expected following a homologous COVID-19 mRNA vaccine booster; however, these reactions appear less common than those following dose 2 of an mRNA-based vaccine. CDC and FDA will continue to monitor vaccine safety and provide data to guide vaccine recommendations and protect public health. SN - 1545-861X UR - https://www.unboundmedicine.com/medline/citation/35176008/Safety_Monitoring_of_COVID_19_Vaccine_Booster_Doses_Among_Adults___United_States_September_22_2021_February_6_2022_ DB - PRIME DP - Unbound Medicine ER -